These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 19616605)

  • 41. Clinical implications of the intrinsic molecular subtypes of breast cancer.
    Prat A; Pineda E; Adamo B; Galván P; Fernández A; Gaba L; Díez M; Viladot M; Arance A; Muñoz M
    Breast; 2015 Nov; 24 Suppl 2():S26-35. PubMed ID: 26253814
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
    Rottenberg S; Jaspers JE; Kersbergen A; van der Burg E; Nygren AO; Zander SA; Derksen PW; de Bruin M; Zevenhoven J; Lau A; Boulter R; Cranston A; O'Connor MJ; Martin NM; Borst P; Jonkers J
    Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17079-84. PubMed ID: 18971340
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ribociclib in HR-positive, HER2-negative breast cancer.
    Burki TK
    Lancet Oncol; 2016 Nov; 17(11):e482. PubMed ID: 27746106
    [No Abstract]   [Full Text] [Related]  

  • 45. Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept.
    Linn SC; Van 't Veer LJ
    Eur J Cancer; 2009 Sep; 45 Suppl 1():11-26. PubMed ID: 19775601
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Triple negative tumours: a critical review.
    Reis-Filho JS; Tutt AN
    Histopathology; 2008 Jan; 52(1):108-18. PubMed ID: 18171422
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities.
    Conlin AK; Seidman AD
    Clin Breast Cancer; 2008 Jun; 8(3):215-23. PubMed ID: 18650151
    [TBL] [Abstract][Full Text] [Related]  

  • 48. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.
    Rodriguez AA; Makris A; Wu MF; Rimawi M; Froehlich A; Dave B; Hilsenbeck SG; Chamness GC; Lewis MT; Dobrolecki LE; Jain D; Sahoo S; Osborne CK; Chang JC
    Breast Cancer Res Treat; 2010 Aug; 123(1):189-96. PubMed ID: 20582464
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase.
    Alli E; Sharma VB; Sunderesakumar P; Ford JM
    Cancer Res; 2009 Apr; 69(8):3589-96. PubMed ID: 19351835
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Potential therapeutic target for triple-negative breast cancer.
    Gilbert JA
    Lancet Oncol; 2012 Aug; 13(8):e330. PubMed ID: 23024992
    [No Abstract]   [Full Text] [Related]  

  • 51. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers.
    Nofech-Mozes S; Trudeau M; Kahn HK; Dent R; Rawlinson E; Sun P; Narod SA; Hanna WM
    Breast Cancer Res Treat; 2009 Nov; 118(1):131-7. PubMed ID: 19189211
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Triple negative and basal-like breast cancer in East Africa.
    Trinkaus ME; Sayed S; Gakinya SM; Moloo Z; Hanna W; Rahim Y
    Breast J; 2011; 17(4):438-40. PubMed ID: 21752138
    [No Abstract]   [Full Text] [Related]  

  • 54. Triple-negative breast cancer: novel therapies and new directions.
    Pal SK; Mortimer J
    Maturitas; 2009 Aug; 63(4):269-74. PubMed ID: 19632796
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer.
    Greenberg S; Rugo HS
    Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S20-9. PubMed ID: 20805062
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.
    Paranjape T; Heneghan H; Lindner R; Keane FK; Hoffman A; Hollestelle A; Dorairaj J; Geyda K; Pelletier C; Nallur S; Martens JW; Hooning MJ; Kerin M; Zelterman D; Zhu Y; Tuck D; Harris L; Miller N; Slack F; Weidhaas J
    Lancet Oncol; 2011 Apr; 12(4):377-86. PubMed ID: 21435948
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based study.
    Musolino A; Michiara M; Bella MA; Naldi N; Zanelli P; Bortesi B; Capelletti M; Soldani L; Camisa R; Martella E; Franciosi V; Savi M; Neri TM; Ardizzoni A; Cascinu S
    Tumori; 2005; 91(6):505-12. PubMed ID: 16457150
    [TBL] [Abstract][Full Text] [Related]  

  • 58. BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer.
    Diaz-Cruz ES; Cabrera MC; Nakles R; Rutstein BH; Furth PA
    Breast Dis; 2010; 32(1-2):85-97. PubMed ID: 21778574
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.
    Horiuchi D; Kusdra L; Huskey NE; Chandriani S; Lenburg ME; Gonzalez-Angulo AM; Creasman KJ; Bazarov AV; Smyth JW; Davis SE; Yaswen P; Mills GB; Esserman LJ; Goga A
    J Exp Med; 2012 Apr; 209(4):679-96. PubMed ID: 22430491
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetics of triple-negative breast cancer: Implications for patient care.
    Afghahi A; Telli ML; Kurian AW
    Curr Probl Cancer; 2016; 40(2-4):130-140. PubMed ID: 28340968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.